{
    "root": "15cd90eb-b3a8-6725-cda0-c3ab23054184",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FINGOLIMOD",
    "value": "20241128",
    "ingredients": [
        {
            "name": "Fingolimod Hydrochloride",
            "code": "G926EC510T"
        },
        {
            "name": "Silicon dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Gelatin, Unspecified",
            "code": "2G86QN327L"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Cellulose, Microcrystalline",
            "code": "OP1R32D61U"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        }
    ],
    "indications": "Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.",
    "contraindications": "Assessments are required prior to initiating Fingolimod capsules. ( 2.1 ) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2 , 2.3 ) Recommended dosage for pediatric patients (10 years of age and above) weighing less than or equal to 40 kg: 0.25 mg orally once daily, with or without food. ( 2.2 , 2.3 ) First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. ( 2.4 , 7.1 )",
    "warningsAndPrecautions": "Fingolimod capsules 0.5 mg are hard gelatine capsules with a white opaque body and bright yellow cap imprinted with Biocon Logo on the cap and “F 0.5” on the body with black ink.\n                        Fingolimod capsules are supplied as follows.\n                        Carton of 28 capsules containing 1 blister card (1 X 28 capsules) - NDC 70377-019-21\n                        Bottle of 30 capsules - NDC 70377-019-11",
    "adverseReactions": "Fingolimod is contraindicated in patients who have:\n                  \n                     \n                        in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure\n                     \n                     a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [see Warnings and Precautions (5.1)]\n                     \n                     a baseline QTc interval ≥ 500 msec\n                     cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs\n                     \n                        had a hypersensitivity reaction to fingolimod or any of the excipients in fingolimod capsules. Observed reactions include rash, urticaria and angioedema upon treatment initiation [see \n                              \n                              Warnings and Precautions (5.14)\n                           ]."
}